8-K: Penumbra Reports Strong Q3 2025 Results, Raises Full-Year Outlook

Penumbra, Inc. announced robust third-quarter 2025 financial results, with revenue up 17.8% to $354.7 million, and increased its full-year 2025 revenue guidance.

Summary

• Revenue for the third quarter of 2025 was $354.7 million, an increase of 17.8% (16.9% in constant currency) compared to the third quarter of 2024.
• Total U.S. revenue in Q3 2025 reached $275.0 million, marking a 21.5% increase over the prior year's third quarter.
• U.S. Thrombectomy revenue grew by 18.5% to $192.0 million in Q3 2025, with U.S. VTE revenue specifically increasing by 34% year-over-year.
• Global thrombectomy product revenue was $236.4 million, up 15.8% (15.1% in constant currency) from the same period last year.
• Global embolization and access product revenue increased by 22.0% (20.8% in constant currency) to $118.3 million.
• Income from operations for Q3 2025 was $48.8 million, resulting in an operating margin of 13.8%.
• Net income for the quarter stood at $45.9 million, with a net income margin of 12.9%.
• Adjusted EBITDA was $66.7 million, achieving an adjusted EBITDA margin of 18.8% in Q3 2025.
• Gross profit for the third quarter of 2025 was $240.4 million, representing 67.8% of total revenue, an improvement from 66.5% in Q3 2024.
• Total operating expenses were $191.6 million, or 54.0% of total revenue, down from 54.8% in Q3 2024.
• Research and development (R&D) expenses decreased to $22.7 million in Q3 2025 from $25.2 million in Q3 2024.
• Sales, general and administrative (SG&A) expenses increased to $168.9 million in Q3 2025 from $139.7 million in Q3 2024.
• The company is increasing its full-year 2025 total revenue guidance to a range of $1.375 billion to $1.380 billion, representing 15% to 16% growth over 2024 revenue of $1.195 billion.
• Guidance for U.S. Thrombectomy growth of 20% to 21% and for both gross margin and operating margin for full year 2025 is maintained.

Sentiment

Score: 8

Explanation: The company reported strong financial results across key metrics, including significant revenue growth, improved profitability, and increased full-year guidance. This indicates robust operational performance and positive market reception for its products, particularly in the U.S. thrombectomy and embolization segments. While international growth was slower and SG&A increased, the overall financial health and outlook are very positive.

Positives

• Strong overall revenue growth of 17.8% in Q3 2025, reaching $354.7 million.
• Exceptional U.S. revenue growth of 21.5% to $275.0 million.
• Robust U.S. Thrombectomy revenue growth of 18.5% and a significant 34% increase in U.S. VTE revenue.
• Global embolization and access products demonstrated strong growth of 22.0%.
• Improved gross margin to 67.8% in Q3 2025 from 66.5% in Q3 2024.
• Substantial increase in income from operations to $48.8 million from $35.4 million in Q3 2024.
• Positive net income of $45.9 million, up from $29.5 million in Q3 2024.
• Adjusted EBITDA increased to $66.7 million from $56.7 million in Q3 2024.
• Operating expenses as a percentage of total revenue decreased to 54.0% from 54.8%.
• Increased full-year 2025 total revenue guidance, indicating strong confidence in continued growth.
• The company maintains its position as the world's leading thrombectomy company.

Negatives

• International revenue growth was lower at 6.6% (3.0% in constant currency) compared to the strong U.S. performance.
• Research and development expenses decreased from $25.2 million to $22.7 million, which could be interpreted as a potential slowdown in new product investment, though it may also reflect efficiency.
• Sales, general and administrative expenses increased significantly by $29.2 million year-over-year.

Risks

• Failure to sustain or grow profitability or generate positive cash flows.
• Failure to effectively introduce and market new products.
• Delays in product introductions.
• Significant competition in the medical device market.
• Inability to further penetrate the current customer base, expand the user base, and increase the frequency of product use by customers.
• Inability to achieve or maintain satisfactory pricing and margins.
• Manufacturing difficulties.
• Permanent write-downs or write-offs of inventory or other assets.
• Product defects or failures.
• Unfavorable outcomes in clinical trials.
• Inability to maintain company culture as it grows.
• Fluctuations in foreign currency exchange rates.
• Potential adverse regulatory actions.
• Potential impact of any acquisitions, mergers, dispositions, joint ventures or investments.

Future Outlook

The company is increasing its guidance for full-year 2025 total revenue to a range of $1.375 billion to $1.380 billion, which represents 15% to 16% growth over 2024 revenue. It maintains guidance for U.S. Thrombectomy growth of 20% to 21% compared to 2024 levels, and also maintains guidance for both gross margin and operating margin for the full year 2025.

Industry Context

Penumbra, as the world's leading thrombectomy company, operates in the rapidly evolving medical device sector, specifically targeting challenging conditions like ischemic stroke, venous thromboembolism, and acute limb ischemia. The strong growth in thrombectomy and embolization products suggests a robust market demand for minimally invasive treatments for vascular conditions, aligning with broader trends in healthcare towards less invasive procedures and improved patient outcomes. The company's focus on innovation and its broad portfolio position it well within this competitive landscape.

Legal Proceedings

• Non-recurring litigation related expenses were incurred during the nine months ended September 30, 2024, as part of non-GAAP adjustments, but no current or ongoing legal proceedings are detailed.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased revenue guidance, and improved profitability, potentially leading to increased share value.
• Employees: Continued growth and expansion may lead to job stability and potential opportunities.
• Customers (Healthcare Providers/Hospitals): Continued innovation and broad product portfolio support improved patient outcomes.
• Suppliers: Increased demand for products may lead to higher orders for suppliers.
• Creditors: Improved financial health and profitability enhance the company's ability to meet its financial obligations.

Next Steps

• Host a conference call on November 5, 2025, at 4:30 PM Eastern Time to discuss the third quarter 2025 financial results.
• Continue developing innovative technologies for challenging medical conditions.
• Support healthcare providers, hospitals, and clinics in over 100 countries.

Key Dates

Recommendation

The company delivered exceptional Q3 2025 results, significantly exceeding prior-year performance with strong revenue growth, improved gross and operating margins, and substantial net income. The upward revision of full-year revenue guidance signals strong momentum and management confidence. As the world's leading thrombectomy company, Penumbra is well-positioned in a high-growth medical device market. While international growth is slower, the robust U.S. performance and product category strength (especially VTE) indicate a healthy core business. The positive financial trajectory and market leadership make it a compelling investment.

Keywords

Penumbra, thrombectomy, embolization, medical devices, Q3 2025, financial results, revenue, EBITDA, healthcare, stroke, VTE, acute limb ischemia, PEN